Fat content, energy value and fatty acid profile of donkey milk during lactation and implications for human nutrition

Giovanni Martemucci and Angela Gabriella D’Alessandro*

Abstract

Background and aims: Milk contains numerous nutrients. The content of n-3 fatty acids, the n-6/n-3 ratio, and short- and medium-chain fatty acids may promote positive health effects. In Western societies, cow’s milk fat is perceived as a risk factor for health because it is a source of a high fraction of saturated fatty acids. Recently, there has been increasing interest in donkey’s milk. In this work, the fat and energetic value and acidic composition of donkey’s milk, with reference to human nutrition, and their variations during lactation, were investigated. We also discuss the implications of the acidic profile of donkey’s milk on human nutrition.

Methods: Individual milk samples from lactating jennies were collected 15, 30, 45, 60, 90, 120, 150, 180 and 210 days after foaling, for the analysis of fat, proteins and lactose, which was achieved using an infrared milk analyser, and fatty acids composition by gas chromatography.

Results: The donkey’s milk was characterised by low fat and energetic (1719.2kJ·kg⁻¹) values, a high polyunsaturated fatty acids (PUFA) content of mainly α-linolenic acid (ALA) and linoleic acid (LA), a low n-6 to n-3 FA ratio or LA/ALA ratio, and advantageous values of atherogenic and thrombogenic indices. Among the minor PUFA, docosahesaenoic (DHA), eicosapentanoic (EPA), and arachidonic (AA) acids were present in very small amounts (<1%). In addition, the AA/EPA ratio was low (0.18). The fat and energetic values decreased (P < 0.01) during lactation. The fatty acid patterns were affected by the lactation stage and showed a decrease (P < 0.01) in saturated fatty acids content and an increase (P < 0.01) in the unsaturated fatty acids content. The n-6 to n-3 ratio and the LA/ALA ratio were approximately 2:1, with values <1 during the last period of lactation, suggesting the more optimal use of milk during this period.

Conclusions: The high level of unsaturated/saturated fatty acids and PUFA-n3 content and the low n-6/n-3 ratio suggest the use of donkey’s milk as a functional food for human nutrition and its potential utilisation for infant nutrition as well as adult diets, particular for the elderly.

Keywords: Donkey’s milk, Energetic value, Fatty acids, Nutritional remarks

Background

The relationship between diet and health is one of the keys for preventing disease and promoting well-being. There is an increasing awareness of the role of dietary lipids in health maintenance and disease prevention. Evidence suggests that a high intake of saturated fatty acids (SFA) from the diet may be associated with elevated cardiovascular disease risk [1], and the association between diet and health is a decisive factor in consumer food selection. In addition to the reduction of fat intake, a change in the saturated/unsaturated fatty acid ratio may contribute to improved human health [2].

A European study on fatty acid consumption reported that milk and dairy products are great sources of SFAs [3].

Cow milk possesses poor polyunsaturated fatty acid (PUFA) levels [4]. Donkey’s milk appears to contain lower SFA amounts and higher essential fatty acid (EFA)
amounts than cow’s milk, although it appears to feature limited amounts of long-chain PUFA; overall these findings suggest that donkey’s milk is more like human milk than is cow’s milk [5].

Recently, there has been increasing interest in donkey’s milk due to its potential role in human nutrition and especially in paediatric dietetics [6-8].

The determination of the characteristics of donkey’s milk is important for economic interest in human diets and pharmaceuticals. Moreover, the milk composition is affected by the stage of lactation [9,10].

Few studies on the characterisation of the lipid content and energetic value of donkey’s milk [11,12] or on the variation in milk fat content, energetic value and fatty acid composition during lactation have been reported [11,13]. Thus, a deeper knowledge of the fat and energetic composition of this milk is necessary to understand the physiological features of milk, particularly the fatty acid composition, which is of great importance from a nutritional standpoint [14].

The aim of this study was to investigate the fat and energetic value and acidic composition of donkey’s milk over seven months of lactation, and several parameters that could be of interest to human nutrition were highlighted.

Methods

The experiment was conducted according to protocols approved by the Italian Minister for Scientific Research in accordance with EC regulations.

Milk samples and analyses

Milk samples were collected during an entire lactation period of seven months (210 days) from nine healthy pluriparous jennies of the Martina Franca breed, aged from 6 to 12 year, with good body conditions (average weight = 320 ± 30 kg; the average body condition was 3.3 ± 0.2 on a scale of 0 to 5 [15]). The animals were reared under the semi-extensive conditions commonly used in the typical breeding area (south-eastern Murcia, Apulia region, southern Italy) (40°37’20” latitude; 60°17’44” longitude), based on natural grazing (7 to 10h of pasture in one grazing session on natural scrub of Ligustrum vulgare L., Arbutus unedo L., Pistacia Lenticus, Quercus ilex L., Fraxinus ornus and Cistus s.p.) with added oats (2 times per day; 2.0 to 2.5 kg grain·d⁻¹·jenny⁻¹) and water ad libitum. The animals were selected according to a close foaling date (± 7 days). During the lactation period the foals were with their dams and were separated from them before milking (3 h). The asses were milked twice a day, in the presence of foals placed in an adjacent box to allow visual contact, using a mechanical milker with a vacuum level of 42 kPa, a pulse ratio of 50% and a pulse rate of 120 cycles/min [16].

Individual milk samples, from morning and evening milkings, were collected 15, 30, 45, 60, 90, 120, 150, 180, and 210 days after foaling. Milk from the two daily milkings was pooled and split into two aliquots for the analyses of fat, protein and lactose content and for the determination of fatty acid composition. The milk samples were then preserved (−20°C) until analysis.

The fat, protein and lactose contents were determined using an infrared milk analyser (MilkoSCAN 6000), previously standardised for donkey’s milk according to FIL-IDF 414C [17] to determine the gross energetic value. The gross energetic value of milk, expressed in kJ·kg⁻¹, was calculated by the Perrin [18] formula, which considers a coefficient of 9.11 for the fat percentage, 5.86 for the protein percentage and 3.95 for the lactose percentage.

The fatty acids composition of the collected milk samples was determined using capillary gas chromatography. The fat content of milk was extracted with chloroform-methanol (2:1, vol/vol) using the method described by Folch et al. [19]. The fatty acid composition in milk was estimated using methyl esters prepared by direct transesterification, according to IUPAC method 2.301 [20]. The analyses were performed using a Fison HRGC Mega 2 series gas chromatograph (Milan, Italy) with a flame-ionisation detector fitted with WCOT fused-silica capillary column (FFAP-CB coating, 25 m × 0.32 mm i.d. × 0.30 μm film thickness, Chrompack, Middleburg, The Netherlands) using the analytical conditions used by Caponio et al. [21]. The separation was performed at pre-programmed temperatures: 50°C for 3 min; 50–100°C at a rate of 20°C/min; 100°C for 2 min; 100–240°C at a rate of 20°C/min; 240°C for 15 min. Hydrogen was the carrier gas (flow rate, 2mL/min). The injector temperature was 270°C (splitting ratio, 1:17) and the detector temperature was 300°C. Fatty acid peaks were identified using a comparative analysis with standard reference mixtures. The fatty acid content is expressed as percentage of the total identified fatty acids.

The desaturase index was calculated for three pairs of fatty acids representing the products and substrates for Δ⁹-desaturase as follows: cis-9 14:1/14:0, cis-9 16:1/16:0, cis-9 18:1/18:0. For example the desaturase index for cis-9 18:1 was (cis-9 18:1)/(cis-9 18:1+18:0). The atherogenic (AI) and thrombogenic (TI) indices were calculated using the Ulbricht and Southgate [22] equations.

Statistical analysis

Changes over time in the fat, energetic values and classes or the individual fatty acids of milk from the jennies were analysed by PROC MIXED for repeated measurements of SAS [23]. A GLM procedure was used. The fixed effect included the stage of lactation which was divided into 8 controls considering post-foaling days (d 15, 30, 60, 90, 120, 150, 180 and 210) for the fat composition and gross
energy content of milk and into 9 controls (d 15, 30, 45, 60, 90, 120, 150, 180 and 210) for the fatty acid composition, with the residual error being individual within a given control of lactation. The differences among the means were compared using Student’s t tests. The results were considered significant when P ≤ 0.05.

Results

Milk fat content and gross energy
The average percentage of milk fat is provided in Table 1 and was low (an average of 0.54%). The highest value occurred at 15 and 30 days with a gradual decreasing trend throughout the lactation period, becoming significant (P < 0.05) at 210 days.

The gross energetic value of donkey’s milk on average was 1748.5 kJ·kg⁻¹, with a significant (P < 0.05) decrease (−10%) from day 15 to 210 (Table 1).

Fatty acid composition
The acid classes of fat milk were statistically different (P < 0.05) and were influenced by the lactation stage (P<0.01). Overall, the average SFA content was higher than the monounsaturated fatty acid (MUFA) and PUFA content (Table 2).

Saturated fatty acids
The SFA content in the milk decreased significantly (P < 0.01) during the lactation period (−33.9%), from an average mean of 62.88% at day 15 to 41.54% at day 180 after foaling and then decreased slightly at day 210 (Figure 1, Table 3a).

Among the SFA, palmitic acid was observed to be the most concentrated (C16:0 = 19.94% average, data not presented). Lower concentration levels were observed for capric (C10:0 = 10.78% average), lauric (C12:0 = 8.78% average), myristic (C14:0 = 6.98% average) and caprylic (C8:0=6.20%) acids, with the lowest level observed for stearic acid (C18:0=1.82% average) (data not presented).

Among the fatty acids found at concentrations greater than 1%, palmitic acid (C16:0) exhibited a significant decrease in concentration at day 30 and day 90 (Tables 4, 3f). The myristic acid (C14:0) concentration decreased significantly from day 15 to day 120, day 150 and day 180 (Tables 4, 3e). Lauric acid (C12:0) exhibited a significant decrease in concentration from day 15 to day 180 (Tables 4, 3d). Caprylic acid (C8:0) showed a slight increase in concentration at day 30, followed by a significant decrease until reaching 3.79% at day 180 (Tables 4, 3b). Capric acid (C10:0), after a slight increase between 15 and 30 days, declined in concentration significantly to 5.86% at day 180 (Tables 4, 3c). The stearic acid concentration did not vary significantly over time (Table 4).

Unsaturated fatty acid
The overall unsaturated fatty acid (UFA) content of the milk was 48.02 ± 2.97% (Table 2) and increased during the lactation period (Figure 1A). The mean UFA/SFA ratio was 0.92, which underwent a significant increase over time, reaching a value greater than 1% at day 120 and a peak of 1.50% at day 180 (Figure 1B, Table 3 g).

The overall MUFA content was 28.00 ± 3.91% (Table 2). The stage of lactation affected (0.05 > P < 0.01) the MUFA content. The total MUFA increased (P<0.01) during lactation from 23.58% at day 15 to 34.40% at day 180 and then decreased slightly at day 210 (Figure 1A, Table 5a). The individual MUFA profiles are reported in Table 4. Oleic acid (C18:1 n-9) was the most representative of MUFA (21.50%, average), with a significant (Table 5 g) increase in concentration at day 30 and day 90 (Tables 4, 3f). The myristic acid (C14:0) concentration decreased significantly from day 15 to day 120, day 150 and day 180 (Tables 4, 3e). Lauric acid (C12:0) exhibited a significant decrease from day 15 to day 180 (Tables 4, 3d). Caprylic acid (C8:0) showed a slight increase at day 30, followed by a significant decrease until reaching 3.79% at day 180 (Tables 4, 3b). Capric acid (C10:0), after a slight increase between 15 and 30 days, declined in concentration significantly to 5.86% at day 180 (Tables 4, 3c). The stearic acid concentration did not vary significantly over time (Table 4).

Table 1 Average fat (% w/w) and gross energy content of milk during the lactation period (210 d)

| Lactation stage | Fat X ± SD | Gross Energy (kJ·kg⁻¹) |
|-----------------|------------|------------------------|
| 15 d            | 0.72 ± 0.09 a | 1857.3 a                |
| 30 d            | 0.71 ± 0.10 a | 1831.5 a                |
| 60 d            | 0.65 ± 0.15   | 1780.9                  |
| 90 d            | 0.54 ± 0.15   | 1749.6                  |
| 120 d           | 0.55 ± 0.17   | 1761.4                  |
| 150 d           | 0.50 ± 0.22   | 1690.6                  |
| 180 d           | 0.48 ± 0.06   | 1668.4                  |
| 210 d           | 0.42 ± 0.33 a | 1645.6 b                |

Table 2 Summarized data of milk fatty acid composition (X ± SD)

| Fatty acid composition | Saturated (SFA, %) | Unsaturated (UFA, %) | Monounsaturated (MUFA, %) | Polyunsaturated (PUFA, %) | PUFA n-3 (%) | PUFA n-6 (%) | PUFA n-3/n-6 ratio | UFA/SFA ratio | Desaturase index¹ | Atherogenic index (AI)² | Thrombogenic index (Th)³ |
|------------------------|--------------------|----------------------|---------------------------|---------------------------|---------------|---------------|---------------------|----------------|-------------------|------------------------|------------------------|
|                        | 51.98 ± 5.13       | 48.02 ± 2.97         | 28.00 ± 3.91              | 20.02 ± 2.04              | 7.12 ± 1.96   | 12.90 ± 2.13  | 0.59 ± 0.08         | 0.92 ± 0.07     | cis-9 14:1        | 0.04 ± 0.01            | 0.14 ± 0.03            |
|                        |                    |                      |                           |                           |               |               |                     |                | cis-9 16:1        | 0.93 ± 0.01            |                       |
|                        |                    |                      |                           |                           |               |               |                     |                | cis-9 18:1        |                       | 1.16 ± 0.28            |
|                        |                    |                      |                           |                           |               |               |                     |                |                   | 0.70 ± 0.14            |                       |

¹Ratio of Δ⁹-desaturase product divided by the sum of the Δ⁷-desaturase product and product.
²Calculated using the equation described by Ulbricht and Southgate (1991).
increase at day 90 and maximum level at day 180 (27.57%). The average palmitoleic acid (C16:1) content was 3.45%. It decreased from early lactation to day 90, then increased significantly (Table 5e), reaching its maximum level at day 210.

Among the MUFAs found at a concentration greater than 1%, the content of decenoic acid (C10:1=1.16%, average) decreased significantly during lactation (Tables 4, 5b). The miristoleic acid (C14:1) content exhibited a decreasing trend, from day 15 to day 180, and then increased at day 210 (Tables 4, 5c).

With respect to milk fatty acid pairs representing product/substrate ratios and related to the Δ⁹-desaturase system (Table 2), a higher desaturase index was observed (P < 0.01) for cis-9 18:1 (0.93, average) than for cis-9 16:1 (0.14, average) and cis-9 14:1 (0.04, average). The stage of lactation affected (P < 0.01) the Δ⁹-desaturase ratios (Table 4), with a significant increase mainly in cis-

Figure 1 Variations of fatty acid composition and indices for human health of milk during the lactation period: (A) saturated (SFA), unsaturated (UFA), monounsaturated (MUFA) and polyunsaturated fatty acids (PUFA); (B) UFA/SFA and PUFA n-3/n-6 fatty acids ratios; (C) atherogenic (AI) and thrombogenic (TI) indices (mean ± SD).
Table 3 Statistical differences in (a) SFA (saturated fatty acids), (b) C8:0, (c) C10:0, (d) C12:0, (e) C14:0, (f) C16:0 and (g) UFA (unsaturated fatty acids)/SFA ratio of milk in relation to the lactation stage of jennies (*: P < 0.05; **: P < 0.01; ns: not significant)

(a) SFA

|          | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|----------|-----|-----|-----|-----|-----|------|------|------|------|
| 15d      | ns  | ns  | ns  | **  | **  | **   | **   | **   | **   |
| 30d      | ns  | ns  | ns  | **  | **  | **   | **   | **   | **   |
| 45d      | ns  | ns  | ns  | ns  | **  | **   | **   | **   | **   |
| 60d      | *   | ns  | ns  | ns  | **  | **   | **   | **   | **   |
| 90d      | ns  | ns  | ns  | ns  | ns  | **   | *    |      |      |
| 120d     | ns  | ns  | ns  | **  | **  | *    | ns   | ns   | ns   |
| 150d     | ns  | ns  | ns  | **  | **  | **   | *    | ns   | ns   |
| 180d     | ns  | ns  | ns  | ns  | ns  | **   | **   | *    | ns   |
| 210d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |

(b) C8:0

|          | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|----------|-----|-----|-----|-----|-----|------|------|------|------|
| 15d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 45d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 60d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 90d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 180d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 210d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |

(c) C10:0

|          | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|----------|-----|-----|-----|-----|-----|------|------|------|------|
| 15d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 45d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 60d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 90d      | *   | ns  | ns  | ns  | ns  | ns   | **   | *    | **   |
| 120d     | **  | *   | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d     | **  | *   | **  | *   | ns  | ns   | ns   | ns   | ns   |
| 180d     | **  | *   | **  | *   | **  | *    | ns   | ns   | ns   |
| 210d     | **  | **  | **  | **  | **  | **   | ns   | ns   | ns   |

(d) C12:0

|          | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|----------|-----|-----|-----|-----|-----|------|------|------|------|
| 15d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 45d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 180d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 210d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |

(e) C14:0

|          | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|----------|-----|-----|-----|-----|-----|------|------|------|------|
| 15d      | *   | ns  | ns  | *   | **  | **   | **   | **   | **   |
| 30d      | ns  | ns  | ns  | *   | ns  | ns   | **   | **   | **   |
| 45d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | **   |
| 60d      | ns  | ns  | ns  | ns  | ns  | ns   | *    | ns   | ns   |
| 90d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 180d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 210d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |

(f) C16:0

|          | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|----------|-----|-----|-----|-----|-----|------|------|------|------|
| 15d      | ns  | ns  | *   | **  | **  | **   | **   | **   | **   |
| 30d      | ns  | ns  | *   | ns  | ns  | ns   | ns   | ns   | ns   |
| 45d      | ns  | ns  | *   | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d      | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d      | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d     | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d     | ns  | *   | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 180d     | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 210d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |

(g) UFA/SFA

|          | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|----------|-----|-----|-----|-----|-----|------|------|------|------|
| 15d      | ns  | ns  | ns  | *   | **  | **   | **   | **   | **   |
| 30d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 45d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 60d      | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 90d      | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 180d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 210d     | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
Table 4 Saturated, monounsaturated, polyunsaturated fatty acid profile (% of fatty acids) and desaturase index during the lactation period (210 days)

| Saturated Fatty Acids (SFA) | LACTATION STAGE | Effect of Lactation stage<sup>1</sup> |
|-----------------------------|-----------------|--------------------------------------|
|                             | 15 d | 30 d | 45 d | 60 d | 90 d | 120 d | 150 d | 180 d | 210 d |
| Butyric Acid C<sub>4:0</sub> | 0.51 | 0.61 | 0.28 | 0.51 | 0.4  | 0.57 | 0.59  | 0.15  | 0.23  | *    |
| Caproic Acid C<sub>6:0</sub> | 0.52 | 0.72 | 0.58 | 0.72 | 0.71 | 0.64 | 0.61  | 0.37  | 0.59  | *    |
| Heptanoic Acid C<sub>7:0</sub> | 0.02 | 0.01 | 0.02 | 0.01 | 0.01 | 0.03 | 0.02  | 0.01  | 0.03  | ns   |
| Caprylic Acid C<sub>8:0</sub> | 5.30 | 6.76 | 6.13 | 6.87 | 6.07 | 4.57 | 4.39  | 3.79  | 4.73  | *    |
| Nonanoic Acid C<sub>9:0</sub> | 0.04 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03  | 0.03  | 0.03  | ns   |
| Capric acid C<sub>10:0</sub> | 12.01 | 13.46 | 11.75 | 11.93 | 9.82 | 7.62 | 7.19  | 5.82  | 6.66  | **   |
| Undecanoic acid C<sub>11:0</sub> | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02  | 0.02  | 0.01  | ns   |
| Lauric acid C<sub>12:0</sub> | 10.82 | 10.87 | 9.47 | 9.27 | 7.55 | 6.42 | 5.84  | 4.44  | 5.32  | **   |
| Tridecanoic acid C<sub>13:0</sub> | 0.04 | 0.05 | 0.06 | 0.06 | 0.05 | 0.04 | 0.03  | 0.03  | 0.04  | ns   |
| Myristic Acid C<sub>14:0</sub> | 8.66 | 7.80 | 7.20 | 6.82 | 5.79 | 5.60 | 5.08  | 3.91  | 4.95  | **   |
| Pentadecanoic Acid C<sub>15:0</sub> | 0.22 | 0.22 | 0.23 | 0.23 | 0.24 | 0.24 | 0.23  | 0.20  | 0.22  | ns   |
| Palmitic Acid C<sub>16:0</sub> | 22.37 | 18.33 | 19.56 | 19.06 | 18.53 | 19.61 | 20.83  | 19.82  | 19.47  | *    |
| Margaric acid C<sub>17:0</sub> | 0.22 | 0.22 | 0.24 | 0.24 | 0.26 | 0.26 | 0.24  | 0.22  | 0.22  | ns   |
| Stearic Acid C<sub>18:0</sub> | 1.88 | 1.48 | 1.64 | 1.99 | 1.68 | 1.75 | 1.52  | 1.49  | 1.44  | ns   |
| Arachidic Acid C<sub>20:0</sub> | 0.10 | 0.09 | 0.08 | 0.09 | 0.09 | 0.10 | 0.08  | 0.09  | 0.07  | ns   |
| Heneicosanoic Acid C<sub>21:0</sub> | 0.03 | 0.04 | 0.02 | 0.04 | 0.03 | 0.02 | 0.02  | 0.03  | 0.02  | ns   |
| Behenic Acid C<sub>22:0</sub> | 0.04 | 0.10 | 0.15 | 0.06 | 0.07 | 0.19 | 0.15  | 0.05  | 0.04  | ns   |
| Lignoceric Acid C<sub>24:0</sub> | 0.06 | 0.11 | 0.07 | 0.08 | 0.09 | 0.09 | 0.06  | 0.08  | 0.06  | ns   |

| Monounsaturated Fatty Acids (MUFA) | LACTATION STAGE | Effect of Lactation stage<sup>1</sup> |
|-----------------------------------|-----------------|--------------------------------------|
| Decenoic Acid C<sub>10:1</sub>   | 1.38 | 1.64 | 1.25 | 1.36 | 1.08 | 0.91 | 0.84  | 0.76  | 1.20  | *    |
| Dodecenioic Acid C<sub>12:1</sub> | 0.17 | 0.18 | 0.14 | 0.15 | 0.11 | 0.11 | 0.10  | 0.08  | 0.13  | ns   |
| Tridecenioic acid C<sub>13:1</sub>| 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | 0.03  | 0.09  | 0.05  | ns   |
| Myristoleic Acid C<sub>14:1</sub>| 0.38 | 0.34 | 0.29 | 0.26 | 0.21 | 0.26 | 0.25  | 0.21  | 0.32  | *    |
| Pentadecenoic acid C<sub>15:1</sub> | 0.07 | 0.08 | 0.08 | 0.06 | 0.07 | 0.07 | 0.06  | 0.06  | 0.08  | ns   |
| Palmitoleic Acid C<sub>16:1</sub> | 3.02 | 2.79 | 2.98 | 2.36 | 2.28 | 3.22 | 4.23  | 4.48  | 5.67  | *    |
| Heptadecenoic Acid C<sub>17:1</sub> | 0.30 | 0.29 | 0.33 | 0.33 | 0.31 | 0.34 | 0.38  | 0.31  | 0.40  | ns   |
| Oleic Acid C<sub>18:1 n-9</sub>  | 17.55 | 16.65 | 18.62 | 19.36 | 21.29 | 23.74 | 25.05  | 27.57  | 23.73  | **   |
| Gadoleic Acid C<sub>20:1 n-9</sub> | 0.25 | 0.31 | 0.37 | 0.42 | 0.45 | 0.49 | 0.38  | 0.39  | 0.34  | ns   |
| Erucic Acid C<sub>22:1 n-9</sub> | 0.40 | 0.31 | 0.64 | 0.44 | 0.75 | 0.81 | 0.59  | 0.46  | 0.37  | ns   |
| Nervonic Acid C<sub>24:1</sub>   | 0.01 | 0.02 | 0.03 | 0.01 | 0.02 | 0.01 | 0.01  | 0.05  | 0.02  | ns   |

| Polyunsaturated Fatty Acids (PUFA) | LACTATION STAGE | Effect of Lactation stage<sup>1</sup> |
|-----------------------------------|-----------------|--------------------------------------|
| Linoleic Acid C<sub>18:2 n-6</sub> | 8.83 | 9.76 | 10.76 | 11.20 | 15.15 | 14.64 | 12.93  | 17.20  | 11.03  | **   |
| Linolenic Acid C<sub>18:3 n-3</sub> | 3.85 | 5.71 | 5.63 | 4.81 | 5.20 | 5.99 | 6.96  | 6.36  | 11.17  | **   |

<sup>1</sup> Martemucci and DAlessandro Lipids in Health and Disease 2012, 11:13

http://www.lipidworld.com/content/11/1/113
Table 4 Saturated, monounsaturated, polyunsaturated fatty acid profile (% of fatty acids) and desaturase index during the lactation period (210days) (Continued)

| Fatty Acid                | C18:4 n-3 | C20:2 n-6 | C20:3 n-3 | C20:4 n-6 | C20:5 n-3 | C20:6 n-3 | C22:2 n-6 | C22:3 n-3 | C22:4 n-6 | C22:5 n-3 | C22:6 n-3 |
|---------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
| Stearidonic Acid          | 0.01      | 0.02      | 0.02      | 0.02      | 0.03      | 0.03      | 0.03      | 0.02      | 0.02      | 0.03      | 0.03      |
| Eicosadienoic Acid        | 0.22      | 0.20      | 0.30      | 0.29      | 0.36      | 0.34      | 0.23      | 0.24      | 0.19      | 0.24      | 0.19      |
| Eicosatrienoic Acid       | 0.03      | 0.03      | 0.03      | 0.03      | 0.04      | 0.03      | 0.03      | 0.04      | 0.03      | 0.04      | 0.03      |
| Arachidonic Acid          | 0.08      | 0.13      | 0.08      | 0.08      | 0.08      | 0.08      | 0.09      | 0.10      | 0.11      | 0.11      | 0.11      |
| Eicosatetraenoic Acid     | 0.10      | 0.10      | 0.14      | 0.14      | 0.13      | 0.13      | 0.16      | 0.14      | 0.24      | 0.24      | 0.24      |
| Eicosapentaenoic Acid     | 0.23      | 0.30      | 0.56      | 0.48      | 0.65      | 0.71      | 0.49      | 0.55      | 0.51      | 0.51      | 0.51      |
| Docosadienoic Acid        | 0.05      | 0.06      | 0.08      | 0.06      | 0.10      | 0.11      | 0.12      | 0.10      | 0.09      | 0.10      | 0.09      |
| Docosatrienoic Acid       | 0.00      | 0.01      | 0.00      | 0.02      | 0.01      | 0.01      | 0.01      | 0.01      | 0.01      | 0.01      | 0.01      |
| Docosatetraenoic Acid     | 0.05      | 0.05      | 0.05      | 0.04      | 0.07      | 0.09      | 0.03      | 0.05      | 0.03      | 0.05      | 0.03      |
| Docosapentaenoic Acid     | 0.04      | 0.03      | 0.07      | 0.03      | 0.03      | 0.04      | 0.04      | 0.13      | 0.05      | 0.05      | 0.05      |
| Docosahesenoic Acid       | 0.04      | 0.01      | 0.03      | 0.02      | 0.02      | 0.02      | 0.02      | 0.03      | 0.02      | 0.02      | 0.02      |

\[ \Delta^9 \text{-desaturase ratios} \]

\[
\begin{array}{cccccccc}
\text{cis-9} 14:1 & 0.04 & 0.04 & 0.04 & 0.04 & 0.03 & 0.04 & 0.05 & 0.06 & 0.06 & * \\
\text{cis-9} 16:1 & 0.12 & 0.13 & 0.13 & 0.11 & 0.11 & 0.14 & 0.16 & 0.17 & 0.22 & ** \\
\text{cis-9} 18:1 & 0.90 & 0.92 & 0.92 & 0.91 & 0.93 & 0.94 & 0.95 & 0.94 & ** \\
\end{array}
\]

\[ ^a \text{Ratio of the } \Delta^9 \text{-desaturase product divided by the sum of } \Delta^9 \text{-desaturase product and product as described in Materials and Methods.} \]

\[ ^b \text{ns (non-significant): } P>0.05; * P<0.05; ** P<0.01. \]
Table 5 Statistical differences in (a) MUFA (monounsaturated fatty acids), (b) C10:1, (c) C14:1, (d) C14:1/C14:0, (e) C16:1, (f) C16:1/C16:0, (g) C18:1 and (h) C18:1/C18:0 of milk in relation to the lactation stage of jennies (*: P < 0.05; **: P < 0.01; ns: not significant)

|        | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
|--------|-----|-----|-----|-----|-----|------|------|------|------|
| (b) C10:1 |
| 15d    | ns  | ns  | ns  | ns  | ns  | *    | **   | **   | **   |
| 30d    | ns  | ns  | ns  | ns  | ns  | **   | **   | **   | **   |
| 45d    | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 60d    | ns  | ns  | ns  | ns  | ns  | ns   | **   | **   | **   |
| 90d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d   | **  | **  | **  | **  | ns  | ns   | ns   | ns   | ns   |
| 150d   | **  | **  | **  | **  | ns  | ns   | ns   | ns   | ns   |
| 180d   | **  | **  | **  | **  | ns  | ns   | ns   | ns   | ns   |
| 210d   | **  | **  | **  | **  | **  | ns   | ns   | ns   | ns   |
| (c) C14:1 |
| 15d    | ns  | ns  | *   | **  | **  | **  | **   | ns   | ns   |
| 30d    | ns  | ns  | ns  | ns  | **  | **  | **   | ns   | ns   |
| 45d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 180d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 210d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| (d) C14:1/C14:0 |
| 15d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 45d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 180d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 210d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| (e) C16:1 |
| 15d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 45d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d   | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 150d   | *   | *   | *   | *   | ns  | ns   | ns   | ns   | ns   |
| 180d   | *   | *   | *   | *   | *   | ns   | ns   | ns   | ns   |
| 210d   | *   | *   | *   | *   | *   | *   | ns   | ns   | ns   |
| (f) C16:1/C16:0 |
| 15d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 45d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d   | *   | *   | *   | *   | ns  | ns   | ns   | ns   | ns   |
| 150d   | *   | *   | *   | *   | *   | ns   | ns   | ns   | ns   |
| 180d   | *   | *   | *   | *   | *   | *   | ns   | ns   | ns   |
| 210d   | *   | *   | *   | *   | *   | *   | *   | ns   | ns   |
| (g) C18:1 |
| 15d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 45d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d   | *   | *   | *   | *   | ns  | ns   | ns   | ns   | ns   |
| 150d   | *   | *   | *   | *   | *   | ns   | ns   | ns   | ns   |
| 180d   | *   | *   | *   | *   | *   | *   | ns   | ns   | ns   |
| 210d   | *   | *   | *   | *   | *   | *   | *   | ns   | ns   |
| (h) C18:1/C18:0 |
| 15d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 30d    | ns  | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 45d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 60d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 90d    | *   | ns  | ns  | ns  | ns  | ns   | ns   | ns   | ns   |
| 120d   | *   | *   | *   | *   | ns  | ns   | ns   | ns   | ns   |
| 150d   | *   | *   | *   | *   | *   | ns   | ns   | ns   | ns   |
| 180d   | *   | *   | *   | *   | *   | *   | ns   | ns   | ns   |
| 210d   | *   | *   | *   | *   | *   | *   | *   | ns   | ns   |
Among the observed UFAs, the contents of PUFAs were lower (P < 0.05) than those of MUFAs (Table 2). The total PUFA contents were affected by the stage of lactation (P < 0.01), increasing (P < 0.01) from day 15 to day 45 and then until day 180 (Figure 1A, Table 6a).

The PUFA n-6 content of milk fat was higher than that of the PUFA n-3 series (Table 2); both increased during lactation. The PUFA n-6 content underwent a significant increase from day 15 (9.19%) to day 90 (15.70%; P < 0.01) reached a maximum value at day 180 (17.65%; P < 0.01) and then decreased at day 210 (11.44%) (data not provided). The PUFA n-3 content increased during the lactation period, reaching a peak at day 210 (12.08%; P < 0.01).

Among the PUFA of the n-6 series, the most abundant acid was linoleic acid (C18:2 n-6, LA=18.38%, average). The LA content was 8.83% at day 15, with a significant increase at day 90 and the highest level at day 180 (17.20%), which was followed by a marked decrease at day 210 (12.08%; P < 0.01).

Among the PUFA of the n-3 series, alpha-linolenic acid (ALA, C18:3 n-3) was the most represented (6.19%, average). The ALA content underwent a significant increase from 3.85% at day 15 to 6.36% at day 150 and reached a maximum level at day 210 (11.17%) (Tables 4, 6d).

Table 6 Statistical differences in (a) PUFA (polyunsaturated fatty acids), (b) PUFA n3/n6 ratio, (c) C18:2, (d) C18:3, (e) AI (atherogenic index) and (f) TI (thrombogenic index) of milk in relation to the lactation stage of jennies (*: P < 0.05; **: P < 0.01; ns: not significant)

| (a) PUFA | (b) n3/n6 | (c) C18:2 | (d) C18:3 |
|---------|-----------|-----------|-----------|
| 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d | 15d | 30d | 45d | 60d | 90d | 120d | 150d | 180d | 210d |
| ns | * | ** | * | ** | ** | ** | ** | ** | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 30d | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 45d | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 60d | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 90d | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 120d | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 150d | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 180d | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |
| 210d | ** | ** | ** | ** | ** | ** | ** | ** | ns | ns | ns | ns | ns | ns | ns | ns | ns | ns |

Discussion

The observed low average milk fat content is consistent with that reported in the literature for donkey's milk.

Martemucci and D'Alessandro Lipids in Health and Disease 2012, 11:113
http://www.lipidworld.com/content/11/1/113
The fat content was affected by the stage of lactation, showing a decreasing trend, which is in agreement with the results observed for the Ragusana breed [10,28], Litoral-Dinaric donkeys [25], mares [9,29,30] and cows [31].

The low fat content of milk and its variations during the lactation period corresponded to a low energetic value with the same trend during lactation. The gross energy content of the milk was similar to that recorded by Salimei et al. [11]. Compared with the energetic value of milk from different species, that of donkey milk is slightly lower than that of mare milk [29,32] and lower than that of cow and human milk [27]. This finding could be a limiting factor in its use in infant nutrition within a diet exclusively based on milk. Thus, it has been suggested that an appropriate modification in the composition of donkey’s milk be made for infant feeding [33] by adding medium-chain triglycerides or sunflower oil [34,35]. However, the low fat content and energetic value of this milk suggests its potential use in hypocaloric human diets.

The decreasing energy content of donkey’s milk during lactation agrees with the trend observed in mares [29,32], although Salimei et al. [11] did not observe any considerable variation in fat content or energy value during lactation, which is likely due to different experimental conditions.

The SFAs were the most representative fatty acids, in agreement with the results of other studies [36,37] and comparable to the composition of mare [38] and human milk [27]; however, its content was observed to be lower than those observed in ruminant milk [5]. The short-chain fatty acids and medium-chain fatty acids contents as in mares, were observed to be lower than those observed in cow’s milk and higher than those observed in human milk [26,39]. The high fatty acid content < C16 content observed in this study, with respect to other monogastric species [9], agrees with the results from equine studies and could be attributed to their synthesis from acetate and 3-hydroxybutyrate, as observed in ruminants, and not from glucose as occurs in monogastrics [9,40]. Furthermore, instead of ruminants, fatty acid de novo synthesis in equines includes parts of C18 next to C4 and C14 and parts of C16 fatty acids [40].

Among the observed SFA, butyric (C4:0) and caproic (C6:0) acids were observed in concentrations less than 1%, as has been observed in mares [26]. The average amounts of caprylic (C8:0), capric (C10:0) and lauric (C12:0) acids were lower than those reported for Ragusana jennies (12.80%, 18.65%, and 10.67%, respectively; [41]); this finding is likely related to differences in breed and/or body conditions. The caprylic (C8:0) acid content was higher compared with that reported for mares (3.1%), cows (1.3%) and human milk (traces) [40]. Among the observed SFAs, palmitic acid (C16:0) was observed at the highest concentration, in agreement with the results reported in other related studies [28,37] and in studies on mares [26]; however, the content was less than that of cow and human milk [26,39].

During the early lactation period (15–30 days), the milk was observed to contain more C4:0 to C14:0 than during the middle (day 120) and late (day 210) lactation periods, most likely due to an increased synthesis of C4 to C14 fatty acids in the mammary gland during the early lactation period, as has been observed in cows [42].

Long-chain fatty acids such as stearic acid (C18:0) were observed in modest amounts, consistent with the results reported for other breeds [37,41] as well as for mares (1.55%) [9,43], while it has been recorded at higher levels in cow and human milk (7-13%) [26,27,37]. As in equines, the low stearic acid content could be attributed to a low stearic acid content in the animals’ diets and to a high activity of Δ9-desaturase on the conversion of stearic acid (C18:0) into oleic acid (C18:1), which is further enhanced by a high palmitoleic acid (C16:1) content [26], as was observed in this study.

The SFA content decreased during lactation. A higher decrease was observed for lauric (C12:0, -59%) and myristic (C14:0, -54.5%) acids and a lower decrease for palmitic acid (C16:0, -17%), likely due to a decrease in the concentration of the precursors of de novo synthesis. A decrease in the short- and medium-chain fatty acid contents during lactation has also been reported in mares [9,44], while small changes in the SFA content have been observed in human milk [45]; additionally, increases in these fatty acid contents have been observed in cow’s milk [46].

From a nutritional standpoint, it has been reported that C18 SFA has a neutral health effect, while C4 to C10 SFAs have positive effects and C12 to C16 SFAs have negative health effects [47]. In particular, SFAs C14 - C16 are considered dangerous because they are associated with high serum LDL-cholesterol concentrations in human subjects [48]. Medium-chain fatty acids are characterised by better absorption than long-chain fatty acids [49]. Furthermore, it has been suggested that equids’ milk is more digestible than cow’s milk, according to experiments performed on rats, and allows for faster evacuation of the stomach [26].

The UFA content, in agreement with other studies (50.69%) [13], was similar to that of mare’s and human milk but higher than that reported for ruminant’s milk (23-32%) [27,41].

The UFA/SFA ratio is comparable to mare’s milk [27] and higher than that recorded in the Ragusana donkey (0.48) and that reported for ruminant’s milk (0.26-0.41) [41,47].
The MUFA content and oleic (C18:1 n-9) and palmitoleic (C16:1 n-7) acid contents were higher than those observed in donkey’s milk by other researchers [11,41], likely due to different experimental conditions; these contents were observed to be similar to those reported for mares but lower than those in human milk (C18:1, 46%) [30].

The MUFA content increased during the lactation period, whereas Chiofalo et al. [28] did not find significant variability throughout lactation in the Ragusana breed, most likely due to different experimental conditions.

In this study, the amount of desaturation, calculated from the ratio of \( \Delta^9 \)-desaturase product/sum of \( \Delta^9 \)-desaturase product and substrate, was relatively high for C18:1 and C16:1 and increased as lactation progressed, reaching higher values at 150 to 210 days of lactation. This result may explain the observed high value of these MUFA s in milk and their increased trend during lactation. Moreover, it has been reported that preformed fatty acids, such as oleic acid, could be derived from mobilisation from adipose tissue or from absorption from the digestive tract, with an increase being observed for a forage diet [26,44], which likely occurred in this study for the asses fed on pasture.

It has been reported that in the human diet the high relative percentage of MUFA has beneficial effects with respect to arterial disease, i.e., it lowers plasma LDL cholesterol and total cholesterol as well as the fibrinolytic activity of circulating plasma by modifying vascular endothelial physiology [50], while the intake of EPA is a risk factor in contracting coronary heart disease [51].

Among PUFAs and EFAs, LA (C18:2 n-6) and ALA (C18:3 n-3) acid were the most representative of PUFA contents in milk and their increased trend during lactation. According to other researchers [19,30], the reasons for this difference could be related to the amounts of these acids in the animals’ diets and the absence of biohydrogenation of fatty acids in the digestive tract before absorption, unlike what occurs in ruminants [53].

In humans, LA has been reported to play a role in the prevention of gastric ulcers. It is a precursor of prostaglandin E that increases with stimulation by linoleic acid [54]. Prostaglandins are involved in the prevention of gastric ulcers through a rise in mucosal protective factors; this prevention is important in foals, which have a certain incidence of gastric ulcers [55].

In agreement with the results of Gastaldi et al. [37], the percentage of ALA was higher compared with that of human’s (1.14%) and cow’s milk (0.48%) whereas the LA content was similar to that reported for human milk.

The ALA content increased during the lactation period, consistent with the results observed for mares [56], and the maximum level was achieved late in the lactation period. This result reflects the higher PUFA n-3/n-6 ratio at the 7th month of lactation (day 210). This higher ratio may be explained by the increase in pasture feeding by jennies on richer grass during the late lactation period. Grass is rich in ALA content, and no biohydrogenation occurs before absorption [30]. Furthermore, higher ALA contents have been reported in milk from asses [57] and mares [26] fed on herbage rather than hay.

AI and TI, which indicate the healthfulness of milk with respect to fatty acid content and their potential to prevent or cause atherosclerosis and thrombosis, were observed to be present in lower quantities than in cow’s milk (2.51 and 1.86, respectively) [58].

It should be noted that LA is the precursor of PUFA n-6, and AA (C20:4 n-6) and ALA are the precursors of PUFA n-3, EPA (C20:5 n-3) and DHA (C22:6 n-3) acids. AA and EPA/DHA are substrates for the formation of eicosanoids [59]. Prostaglandins and leukotrienes are important in controlling several cell activities [60], and DHA is important in the development of the central nervous system [61]. The role of PUFA is important in the development of the neonatal brain as well as in the development of the retina and cognitive functions [62-64]. The high content of n-3 fatty acids in donkey milk could have a significant effect on the development of the neural system, vision and infant growth.

Among the minor PUFA observed in this study, small amounts of EPA, DHA and AA were observed, consistent with other studies on donkey’s milk [11,37,41] and mare’s milk [26]. The percentage of EPA was higher compared with human milk (0.27%); in contrast, the DHA and AA contents were lower (0.40 and 0.59%) [37]. The reasons for this result are likely due to the different elongation and desaturation processes in mammary glands. A higher AA/EPA ratio in breast milk from the mothers of atopic infants compared with non-atopic infants [65] and the relationship between lower levels of EPA and the early development of atopic disease have been reported. The low AA/EPA ratio observed in this study (0.18), with respect to those reported for human’s and cow’s milk (29.5 and 3.67) [37], suggests that donkey milk could be used in childhood nutrition to prevent the risk of developing atopic diseases. Moreover, donkey’s milk could be useful in pre-term infants’ diets because premature infants seem able to form AA from linoleic acid and EPA and DHA from α-linolenic acid [66,67]. The positive effects of donkey’s milk in infant nutrition has been demonstrated in the treatment of multiple food intolerances [34,68,69] and in selected cases of cow’s milk allergies [7,70].
The high recorded amounts of PUFAs in donkey milk suggest that this milk may also be used adult human diets. From a nutritional point of view, it has been reported that the rapid changes in the diet of the Western industrialised society, mainly over the last 150 years with respect to the ancestor-constituted genetic profile, involve a particular increase in saturated fats and n-6 fatty acids and a decrease in n-3 fatty acids [71-74]. The levels of long-chain n-6 to n-3 (mainly LA compared with ALA) fatty acids are important, particularly n-3 fatty acids [75], in maintaining cardiovascular health [76,77] and they influence the ratios of ensuing eicosanoids and metabolic functions [59]. The dietary balance of the ratios of n-6 to n-3 PUFA affects the regulation of metabolic functions [78] and the development of metabolic syndrome, including lipid profile and adiposity, insulin sensitivity and inflammation [79,80]. It has been estimated that the ratio of n-6 to n-3 fatty acids in the Western diet is 15-20/1, and more n-3 than n-6 fatty acids have been suggested, with a ratio that tends towards 1:1 [81].

In this study, the PUFA n-6 to n-3 ratio and the LA/ALA ratio, in particular, were approximately 2:1, with a lower value (<1) during the 7th month of lactation due to a high increase in the ALA content, potentially suggesting the more optimal use of milk collected during this period.

In addition to the benefits related to coronary health disease, the beneficial health effects of n-3 fatty acids include those related to inflammatory disease, such as rheumatoid arthritis [82], dermatitis [83,84], cancer [85], depression and dementia, and may be potentially used to treat late-onset Alzheimer’s disease [86,87].

Long-chain PUFA n-3 has been shown to induce immunomodulatory activity on natural and acquired immunity [88,89] through the synthesis of lipid mediators (prostaglandins, leukotrienes), peptide mediators (cytokines), reactive oxygen species (superoxide), and enzymes. The metabolites of n-3 fatty acids are less inflammatory than those of n-6 (in particular, AA). The eicosanoid derived from AA, i.e, prostaglandin E2 and leukotriene B4, promote atopic inflammation; in contrast, PUFA n-3 and their derived eicosanoid influence AA metabolism, promoting anti-inflammatory properties [90,91]. The high PUFA n-3 content in donkey’s milk could have a functional effect on the immunological system. In our study on an in vitro model of human peripheral blood mononuclear cells [6,92], donkey milk exhibited the ability to induce IgG secretion and the release of interleukins (IL-12, IL-1β, IL-10) and TNF-α - important to the immunomodulation of immune-related disease - and a high release of nitric oxide (NO), a potent promoter in the prevention of atherosclerosis. Indeed, NO is a strong vasodilator of terminal vessels, improves blood flow, and is an effective antimicrobial agent in the development of atherosclerosis [93]. In combination, these results support the concept that donkey’s milk, likely due to its high PUFA n-3 content, can prevent atherosclerosis via the production of NO and, at moderate intake level (200 mL/d; [94]), can up-regulate the immune response in elderly hosts.

Conclusions

Donkey milk is characterised by low fat and energetic values, a high PUFA content composed mainly of ALA (18:3 n-3) and LA (18:2 n-6), a low ratio of n-6 to n-3 fatty acids or LA/ALA ratio and advantageous values of AI and TI. Among minor PUFA, DHA, EPA, and AA were present in minute amounts.

The fat and energetic values decreased during lactation. The fatty acids patterns were influenced by the lactation stage, showing a decrease in SFA content and an increase in UFA content, with higher values being recorded during the late lactation period. During this period, lower values of the n-6/n-3 ratio (<1) were also observed. The higher PUFA n-3 content and lower PUFA n-6/n-3 and AA/EPA ratios of donkey’s milk with respect to cow’s milk may be of particular interest in adopting donkey’s milk for infant nutrition. Considering the low lipid and energetic value content, donkey’s milk could be used within well-balanced and integrated hypocaloric diets. The recorded high PUFA content and low n-6/n-3 or LA/ALA ratios in donkey milk could make it interesting for adult human nutrition.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

All authors have read and approved the final manuscript. AGD is the leading scientist in this study, AGD and GM contributed and approved the final manuscript. They conceived and carried out the study design, participated in the chemical analysis of milk lipids, as well as analyzing the data, performing the statistical analysis and drafting the manuscript.

Acknowledgements

This research was supported by INTERREG IIIA Greece-Italy (Project Code: I2101030) Paper N. 34 and by a grant from the University of Bari Aldo Moro (Bari, Italy).

We would like to thank Dr C Summo and M T Bilancia for performing the gas chromatographic analysis of the milk fatty acids.

Received: 16 March 2012 Accepted: 3 July 2012
Published: 11 September 2012

References

1. Mensink RP, Zock PL, Kester AD, Katan MB: A meta-analysis of 60 controlled trials. Am J Clin Nutr 2003, 77:1146–1155.
2. Noble RC: Animal supplies of omega-3 fatty acids for human nutrition. Progr Nutr 1999, 14:1–13.
3. Hulslof KF, van Erp-Baart MA, Anttolainen M, Becker W, Church SM, Couet C, Hermann-Kunz E, Kesteloot H, Leth T, Martins I, Moreiras O, Moschandreas J, Pizzoferrato L: Rimestad A H, Thorgeirsdottir H, Van Amelsvoort JM, Aro A, Kafatos A G, Lanzmann-Petithory D, Van Poppel G: Intake of fatty acids in Western Europe with emphasis on trans fatty acids. The TRANSFAIR study. Eur J Clin Nutr 1999, 53:143–157.
4. Chilliland Y, Ferlay A, Mansbridge RM, Doreau M: Ruminant milk fat plasticity: nutritional control of saturated, polyunsaturated, trans and conjugated fatty acids. Annu Zootec 2000, 49:181–205.

5. Chiofalo B, Salimei E, Chiofalo L: Acidi grassi nel latte d’asina: proprietà bio-nutrizionali ed extranutrizionali. Large Animals Review 2003, 6:21–26.

6. Tafaro A, Magrone F, Jirillo F, Marzucchi G, D’Alessandro AG, Amanti L, Jirillo E: Immunological properties of donkey’s milk: its potential use in the prevention of atherosclerosis. Curr Pharm Des 2007, 13:3711–3717.

7. Tesse R, D’Alessandro AG, Pagliuca C, Rizi D, Bozza S, Martemucci G, Armenio L: Does donkey’s milk may represent an alternative dietary support in patients with cow’s milk-induced IgE-mediated and non-IgE-mediated disorders? Case reports [abstract]. Barcelona, Spain: In Proceedings of the XXVIII Congress European Academy of Allergology and Clinical Immunology; 2008:467.

8. D’Alessandro AG, Marzucchi G, Jirillo E, De Leo V: Major whey proteins in donkey’s milk: effect of season and lactation stage. Implications for potential dietary interventions in human diseases. Immunopharmacol Immunotoxicol 2011, 33(2):259–265.

9. Doreau M, Boulot S: Recent knowledge on mare milk production: a review. Livest Prod Sci 1989, 22:213–235.

10. Goscul C, Abalos M, Russo G, Alicata ML, Torrisi C: Bio-nutrizionali ed extranutrizionali. E: Immunological properties of donkey’s milk during lactation. Campobasso, Italy: In Proceedings of the 6th Congress New Findings in equine practice; 2004:77–84.

11. Mariani P, Summer A, Martuzzi F, Formaggioni P, Sabbioni A, Catalano AL: Physicochemical properties, gross composition, energy value and nitrogen fractions of Haflinger nursing mare milk throughout 6 lactation months. Anim Res 2001, 50:415–425.

12. Doreau M, Martuzzi F, In Nutrition and feeding of the broodmare: Milk yield of nursing and dairy mares. EAAP publication No. 120, Wageningen Academic Publishers; N. Miraglia, W. Martin-Rosset; 2006:57–64.

13. Freeze BS, Richards TJ: Lactation curve estimation for use in economic optimization models in the dairy industry. J Dairy Sci 1992, 75:269–339.

14. Burns HD, Gibbs PG, Potter GD: Milk-energy production by lactating mares. Equ Vet Sci 1992, 12:118–120.

15. Rastani F, Beretta B, Fiocchi A, Ballabio C, Galli CL: Cross-reactivity between mammalian proteins. Ann Allergy Asthma Immunol 2002, 89(Suppl 1):11–15.

16. Carroccio A, Cavataio F, Montalto G, D’Amico D, Abate E, Iacono G: Intolerance to hydrolysed cow’s milk proteins in infants: clinical characteristics and dietary treatment. Clin Exp Allergy 2000, 30:1597–1603.

17. Iacono G, Scalli C, D’Amico D, D’Amico A, Di Prima L, Pirrone G, Ambrosiano G, Carroccio A, Iannolingno G: Il latte di asina nel trattamento della stips allergica in età pediatrica: efficacia e valore nutrizionale. Palermo, Italy: In Proceedings of the 2nd Congress Nazionale sull’Asino; 2006:108–110.

18. Doreau M, Bagoll C, Chiofalo E, In Nutrition and feeding of the broodmare. Il latte di asina nel trattamento della stips allergica in età pediatrica: efficacia e valore nutrizionale. Palermo, Italy: In Proceedings of the 2nd Congress Nazionale sull’Asino; 2006:108–110.

19. Iacono G, Scalli C, D’Amico D, D’Amico A, Di Prima L, Pirrone G, Ambrosiano G, Carroccio A, Iannolingno G: Il latte di asina nel trattamento della stips allergica in età pediatrica: efficacia e valore nutrizionale. Palermo, Italy: In Proceedings of the 2nd Congress Nazionale sull’Asino; 2006:108–110.

20. Iacono G, Scalli C, D’Amico D, D’Amico A, Di Prima L, Pirrone G, Ambrosiano G, Carroccio A, Iannolingno G: Il latte di asina nel trattamento della stips allergica in età pediatrica: efficacia e valore nutrizionale. Palermo, Italy: In Proceedings of the 2nd Congress Nazionale sull’Asino; 2006:108–110.

21. Iacono G, Scalli C, D’Amico D, D’Amico A, Di Prima L, Pirrone G, Ambrosiano G, Carroccio A, Iannolingno G: Intolerance to hydrolysed cow’s milk proteins in infants: clinical characteristics and dietary treatment. Clin Exp Allergy 2000, 30:1597–1603.

22. Doreau M, Boulot S, Bauchart D, Barlet JP, Martin-Rosset W: Voluntary intake, milk production and plasma metabolites in nursing mares fed two different diets. J Nutr 1992, 122:992–999.

23. Peak J, Wójtowicz J: Fat and cholesterol content and fatty acid composition of mares’ colostrums and milk during five lactation months. Livest Prod Sci 2008, 118:285–290.

24. Jensen RG, Ferris AM, Lammi-Keef CJ, Henderson RA: Lipoins of bovine and human milk. J Dairy Sci 1990, 73:223–240.

25. Luzzini JL, Anissim F, Bickerstaffe RJ, Jeffcott LB: Mammary and whole-body metabolism of glucose, acetate, palmitate in the lactating horse. Proc Nutr Soc 1972, 31:72A–73A.

26. Chilliland Y, Ferlay A, Mansbridge RM, Doreau M: Ruminant milk fat plasticity: nutritional control of saturated, polyunsaturated, trans and conjugated fatty acids. Annu Zootec 2000, 49:181–205.

27. Malacarne M, Martuzzi F, Amariani P: Protein and fat composition of mares’ milk: some nutritional remarks with reference to human and cow’s milk. Intern Dairy J 2002, 12:869–877.

28. Doreau M, Boulot S, Bauchart D, Barlet JP, Martin-Rosset W: Voluntary intake, milk production and plasma metabolites in nursing mares fed two different diets. J Nutr 1992, 122:992–999.

29. Peak J, Wójtowicz J: Fat and cholesterol content and fatty acid composition of mares’ colostrums and milk during five lactation months. Livest Prod Sci 2008, 118:285–290.

30. Jensen RG, Ferris AM, Lammi-Keef CJ, Henderson RA: Lipoins of bovine and human milk. J Dairy Sci 1990, 73:223–240.

31. Luzzini JL, Anissim F, Bickerstaffe RJ, Jeffcott LB: Mammary and whole-body metabolism of glucose, acetate, palmitate in the lactating horse. Proc Nutr Soc 1972, 31:72A–73A.

32. Palmquist DL, Beaulieu AD, Barbano DM: Feed and animal factors influencing milk fat composition. J Dairy Sci 1993, 76(1753–1771).

33. Carroccio A, Cavataio F, Montalto G, D’Amico D, Abate E, Iacono G: Intolerance to hydrolysed cow’s milk proteins in infants: clinical characteristics and dietary treatment. Clin Exp Allergy 2000, 30:1597–1603.

34. Chilliland Y, Ferlay A, Mansbridge RM, Doreau M: Ruminant milk fat plasticity: nutritional control of saturated, polyunsaturated, trans and conjugated fatty acids. Annu Zootec 2000, 49:181–205.
52. Giosue C, Capper JL, Maniaci G, Bauman DL, Mazza F, Albicò E. Effects of foal presence at milking and dietary extra virgin olive oil on jennet milk fatty acids profile. Ital J Anim Sci 2009, 8(Suppl 2):712–714.

53. Palmquist DL, Lock AL, Shingfield KJ, Bauman DE, in Advances in Food and Nutrition Research: Biosynthesis of conjugated linoleic acid in ruminants and humans. San Diego, California: Elsevier Academic Press; Taylor & Francis; 2005:179–217.

54. Grant HA, Palmer KR, Kelly RW, Wilson NH, Misiewicz JJ. Dietary linoleic acid, and prostaglandin secretion. Gastroenterology 1988, 94:955–959.

55. Sanchez LC, Lester GD, Merritt AM. Effect of ranitidine on intragastric pH in clinically normal neonatal foals. J Am Vet Med Assoc 1998, 212:1407–1412.

56. Orlando M, Goracci J, Curadi M. Fat composition of mare's milk with reference to human nutrition. Ann Fac Vet Med Univ. Pisa 2003, 2097–105.

57. Chioldo B, Poldoni M, Costa R, Salmeri E. Fresh forage in dairy ass's ration: effect on milk fatty acid composition and flavours. Ital J Anim Sci 2005, 4(Suppl 2):433–435.

58. Alired SL, Dhiman TR, Brennand CP, Khanal RC, McMahon DJ, Luchini ND. Milk and cheese from cows fed calcium salts of palm and fish oil alone or in combination with soybean products. J Dairy Sci 2006, 89:234–248.

59. Williams CM. Dietary fatty acids and human health. Ann Zootec 2000, 49:165–180.

60. Innis SM. Polyunsaturated fatty acids in human milk: an essential role in infant development. Adv Exp Med Biol 2004, 554:27–43.

61. Wurtman RJ. Synapse formation and cognitive brain development: effect of docosahexaenoic acid and other dietary constituents. Metabolism 2008, 57(Suppl 1):256–510.

62. Neuriger M, Connor WE, Lin DS, Barstad L, Luck S. Biochemical and functional effects of prenatal and postnatal omega-3 fatty acid deficiency on retina and brain rhesus monkeys. Proc Nat Acad Sci USA 1986, 83(11):4021–4025.

63. Al MD, van Houwelingen AC, Homstra G. Long-chain polyunsaturated fatty acids, pregnancy, and pregnancy outcome. Am J Clin Nutr 2000, 71(Suppl 2):285–2915.

64. Fleeth M, Gandin MT. Dietary PUFA for preterm and term infants: review of clinical studies. Crit Rev Food Sci Food Sci 2005, 45:205–229.

65. Duchêne K, Björkstén B. Efficiency of donkey milk in treating atopic dermatitis: possible role of exogenous L-arginine. J Pediatr Gastroenterol Nutr 2012, 54:177–181.

66. Carnielli VP, Wattimena JJ, Luijendijk IHT, Desenhrat HJ, Sauer PJJ. Fat composition of mare's milk with reference to human nutrition. Crit Rev Food Sci Nutr 2005, 45:229.

67. Giovannini M, Riva E, Agostoni C. The role of dietary polyunsaturated fatty acids during the first 2years of life. Early Hum Dev 1998, 53(Suppl 1):99–107.

68. Iacono G, Carroccio A, Cavatorta F, Montalto G, Soressi M, Balsamo V. Use of ass' milk in multiple food allergy. J Pediatr Gastroenterol Nutr 1992, 14:177–181.

69. Carroccio A, Cavatorta F, Montalto G, Soressi M, Balsamo V. Use of ass'milk in multiple food allergy. J Pediatr Gastroenterol Nutr 1992, 14:177–181.

70. Monti G, Bertino E, Muratore MC, Cossia A, Cresi F, Silvestro L, Fabris C, Fortunato D, Guiffrida MG, Conti A. Efficiency of donkey's milk in treating highly problematic cow's milk allergic children: an vivo and in vitro study. Pediatr Allergy Immunol 2007, 18:258–264.

71. Eaton SB, Konner M. Paleolithic nutrition. A consideration of its nature and current implications. N Engl J Med 1981, 303:383–389.

72. Eaton SB, Konner M, Shostak M. Stone agers in the fast lane: chronic degenerative diseases in evolutionary perspective. Am J Med 1988, 84:739–749.

73. Simopoulos AP. Overview of evolutionary aspects of w3 fatty acids in the diet. World Rev Nutr Diet 1998, 83:1–11.

74. Simopoulos AP. Genetic variation and evolutionary aspects of diet, in: Antioxidants in Nutrition and Health. Boca Raton: CRC Press; Papas A; 1999:65–88.

75. Willett WC. The role of dietary n-6 fatty acids in the prevention of cardiovascular disease. J Cardiov Med (Hagerstown) 2007, 8(Suppl 1):542–545.

76. Okuyama H. High n−6 to n−3 ratio of dietary fatty acids rather than serum cholesterol as a major risk factor for coronary heart disease. Eur J Lipid Sci Technol 2001, 103:418–422.

77. Griffin BA. How relevant is the ratio of dietary n−6 to n−3 polyunsaturated fatty acids to cardiovascular disease risk? Evidence from the OPTILIP study. Curr Opin Lipidol 2008, 19:57–62.

78. Burghardt PR, Kemmerer ES, Bush BJ, Osetek AJ, Yan C, Koch LG, Britton SL, Evans SJ. Dietary n-3:n-6 fatty acid ratios differentially influence hormonal signature in a rodent model of metabolic syndrome relative to healthy controls. Nutr Metab 2010, 7:53. doi:10.1186/1743-7075-7-53.

79. Carpenter YT, Portois L, Malaisse WJ. n-3 fatty acids and the metabolic syndrome. Am J Clin Nutr 2006, 83(Suppl 6):1495S–1504S.

80. Hobbelt JR, Nieminen LR, Blasbalg TL, Rigg LS, Lands WE. Healthy intakes of n-3 and n-6 fatty acids: estimations considering worldwide diversity. Am J Clin Nutr 2006, 83(Suppl 6):1483S–1495S.

81. Simopoulos AP. The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 2008, 233:674–688.

82. Simopoulos AP. Omega-3 fatty acids in inflammation an autoimmune diseases. J Am Coll Nutr 2002, 21:495–505.

83. Horrobin DF. Essential fatty acid metabolism and its modification in atopic eczema. Am J Clin Nutr 2000, 71:5367–372.

84. Olivry T, Marsella R, Hillier A. The ACVD task force on canine atopic dermatitis: are essential fatty acids effective? Vet Immunol Immunopathol 2001, 81:547–362.

85. Dupont YG, Meguid MA, Pichard C. Colon cancer therapy: new perspectives of nutritional manipulations using polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2007, 10:427–432.

86. Ma QL, Teter B, Ubeda OJ, Morihara T, Dhoott D, Nyby MD, Tuck ML, Frautschy SA, Cole GM. Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention. J Neurosci 2007, 27:14299–14307.

87. Ruxton CH, Reed SC, Simpson MJ, Millington KJ. The health benefits of omega-3 polyunsaturated fatty acids: a review of the evidence. J Hum Nutr Diet 2007, 20:275–285.

88. Calder PC. Dietary fatty acids and the immune system. Lipids 1999, 34(Suppl 6):5137–5140.

89. Calder PC. Polyunsaturated fatty acids, inflammation and immunity. Lipids 2001, 36:1007–1024.

90. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnology 2006, 1(20):439.

91. Calder PC. Omega-3 fatty acids and inflammatory processes. Nutrients 2010, 2:355–374.

92. Amati L, Marselli G, Martelli M, Tafaro A, Jirillo F, Fugliews V, Martemucci G, D'Alessandro AG, Jirillo E. Donkey and goat milk intake and modulation of the human aged immune response. Curr Pharm Des 2010, 16:864–869.

93. Turner C, Bilgin HM, Obay BD, Diken H, Armaca M, Kelle M. Effect of nitric oxide in phagocytic activity of lipopolysaccharide induced macrophages: possible role of exogenous L-arginine. Cell Bio Int 2007, 31:565–569.

94. Jirillo E, D'Alessandro AG, Amati L, Tafaro A, Jirillo F, Fugliews V, Martemucci G. Modulation of the human aged immune response by donkey milk intake (abstract). Cite, Grece in Proceedings of the 61st Annual EAAP Meeting; 2010045.

doi:10.1186/1476-511X-11-113

Cite this article as: Martemucci and D'Alessandro. Fat content, energy value and fatty acid profile of donkey milk during lactation and implications for human nutrition. Lipids in Health and Disease 2012 11:113.